Xi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xi Chen has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Honghai Wu
Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
17 shared publications - Qiaojun He
Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
17 shared publications Fengqi Yao
15 shared publicationsGuikai Liang
15 shared publicationsXiaqing Xu
15 shared publicationsYuli Qian
15 shared publications
Latest Publications
- Open Access
- 28 July 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (10) , 4337
Author correction to ‘Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA’ [Acta Pharmaceutica Sinica B 13 (2023) 2585–2600]
- 28 July 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (10) , 4337
Open AccessAuthor correction to ‘Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA’ [Acta Pharmaceutica Sinica B 13 (2023) 2585–2600]
- Open Access
- 17 April 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (6) , 2585-2600
Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
- 17 April 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (6) , 2585-2600
Open AccessMevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
PARP inhibitors upregulate the protein level of PD-L1.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
PARP inhibitors upregulate the protein level of PD-L1.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Increased PD-L1 expression is associated with enhanced STAT3 phosphorylation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Increased PD-L1 expression is associated with enhanced STAT3 phosphorylation.